Watch for the September 15 investor call for operational updates and guidance. The resolicitation of share authorization and reverse split proposals is critical for capital flexibility; failure again would pressure the stock. Monitor BioNX Surgical backlog conversion and hospital channel traction.
Price Chart
Executive Summary
NexGel reported Q2 2026 revenue of $3.69 million and a net loss of $2.87 million. The quarter included $795k backlog in the new BioNX Surgical division, a $144k SilverSeal inventory recall, and integration challenges following the April 2026 Celularity transaction. Key developments include a failed proxy vote for share authorization, a plan to resolicit standalone proposals, and an upcoming investor call. The results are mixed, with forward-looking commentary on hospital channel expansion and a BioNX Regenerative Eye Health launch.
Key Financial Metrics
Key Facts
- Q2 2026 revenue totaled $3.69 million vs consensus $4.3M (miss).
- Net loss was $2.87 million, including $756k amortization, $274k transaction costs, and $144k SilverSeal recall.
- BioNX Surgical backlog was approximately $795,000.
- Shareholder proxy proposal to increase authorized shares and reverse split failed; company will resolicit standalone proposals.
- Integration of Celularity acquisition and surgical channel ramp slower than anticipated.
- Company expects to host an investor update call on or around September 15, 2026.
Financial Impact
Revenue miss of ~$610k vs consensus. Net loss of $2.87M driven by $1.17M in non-recurring/non-cash items.
Risk Factors
- Slower-than-expected integration of Celularity acquisition and surgical channel ramp.
- Supply chain constraints on product availability impacting BioNX Surgical backlog conversion.
- Risk of dilutive financing if share authorization and reverse split proposals fail.
- Low cash buffer ($710k restricted pre-release; released post-quarter-end) limits operational runway.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-038637 |
| Exhibit: ex99-1.htm | 0001493152-26-038637 |
| Document: 0001493152-26-038637-index-headers.html | 0001493152-26-038637 |
| Document: 0001493152-26-038637-index.html | 0001493152-26-038637 |
| Document: 0001493152-26-038637.txt | 0001493152-26-038637 |
| 8-K Data (Synthetic) | 0001493152-26-038637 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 19d ago | 8-K | $3.00 | awaiting T+20 | — | $5.03 (+67.67%) |
Sep 24, 2026 4w ago | 8-K | $3.48 $5.03 | ▲ +44.54% | ▲ +46.02% | $5.03 (+44.54%) |
Aug 20, 2026 9w ago | S-1 | $0.3873 $0.2658 | ▲ +31.37% | ▲ +31.37% | $5.03 (−1198.73%) |
Aug 17, 2026 10w ago | 8-K | $0.3755 $0.2811 | ▲ +25.14% | ▲ +23.16% | $5.03 (−1239.55%) |
Jul 2, 2026 16w ago | 8-K | $0.5646 $0.4438 | ▼ −21.40% | ▼ −20.98% | $5.03 (+790.90%) |
Jun 17, 2026 18w ago | 8-K | $0.5660 $0.4331 | ▼ −23.48% | ▼ −24.01% | $5.03 (+788.69%) |
May 18, 2026 23w ago | Insider Cluster | $0.6140 $0.6110 | ▼ −0.49% | ▼ −1.47% | $5.03 (+719.22%) |
May 12, 2026 23w ago | Press Release | $0.5800 | awaiting T+20 | — | $5.03 (+767.24%) |
Mar 12, 2026 32w ago | Press Release | $0.9560 $0.5720 | ▼ −40.17% | ▼ −42.14% | $5.03 (+426.15%) |
Mar 10, 2026 32w ago | Press Release | $0.9520 $0.6380 | ▼ −32.98% | ▼ −32.83% | $5.03 (+428.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers